TP53 mutations in AML confer resistance to CAR T-cell therapy through exhaustion of CAR T-cells, and dysregulation of the mevalonate and Wnt pathways in AML and CAR T-cells, respectively. Targeting ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

AML is a clonal stem cell cancer characterized by the proliferation and maturation arrest of immature myeloid precursor cells, leading to bone marrow failure (Venugopal and Sekeres, 2024). The ...

This manuscript provides a single-cell transcriptomic atlas for AML (222 samples comprising 748,679 cells) integrating data from multiple studies. They use this dataset to investigate t(8;21) AML, and ...

in ASXL1 mutated colorectal cancer cell lines, will be presented on Monday, June 2, 2025, 1:30 PM-4:30 PM CDT. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML ...

The authors confirm that telomeres in telomerase-positive cells terminate ... the origin of the ssDNA captured in ALT cells, and the occurrence of variant telomere repeats in the cell lines studied. A ...

The lung cancer cell lines (H522, HCC827, H1975, A549, and H1299) and human normal lung epithelial cells (BEAS-2B) were purchased from iCell Bioscience Inc (Shanghai, China) and cultured in Dulbecco’s ...

A group of researchers at Osaka University has developed a new immune cell therapy that could be applied to patients of acute myeloid leukemia, or AML, a type of hematological cancer. Many AML ...